CliffBio
small molecule

DURYSTA

BIMATOPROST

Loss of exclusivityOctober 2034latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameDURYSTA
Active ingredientBIMATOPROST
Strength10MCG
Dosage formIMPLANT
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalMarch 2020
Marketing statusRX

Listed patents

PatentExpiresType
9980974October 2034use U-2759
9492316October 2034product
8629185July 2031substance, product
7799336April 2029product
8206737April 2027use U-2759
10441543December 2026product
9149428December 2026product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DURYSTA patent cliff — loss of exclusivity October 2034 | CliffBio